Intestinal barrier function improvement

"Intestinal barrier function improvement" is not a specific molecular target but rather refers to enhancing the overall integrity and physiological performance of the gut's multilayered defense system. The **intestinal barrier** comprises several components including mucus layers, antimicrobial proteins, tightly joined epithelial cells with regulated turnover/apoptosis rates, detoxifying enzymes like **intestinal alkaline phosphatase**, immune cell populations within the lamina propria, and regulatory receptors such as peroxisome proliferator activated receptor-gamma (PPARγ) or farnesoid X receptor. Disruption in any component can lead to increased permeability ("leaky gut"), allowing bacteria or their products into systemic circulation—contributing to inflammation and metabolic diseases. Therapeutic strategies focus on restoring these layers using agents like curcumin (which boosts IAP), probiotics that support epithelial health through various signaling pathways or modulation of mucus production/composition, prebiotics that foster beneficial microbiota growth, or small molecules targeting nuclear hormone receptors involved in mucosal homeostasis. Because "intestinal barrier function improvement" is a therapeutic goal rather than a discrete molecule/receptor/protein/gene entity itself—and encompasses multiple targets—it should not be classified as a canonical drug target.

Other names

Intestinal barrierGut barrierIntestinal epithelial barrierMucosal barrier

Curcumin increases activity of intestinal alkaline phosphatase and improves tight junction integrity to reduce paracellular transport and inflammation. Probiotics promote proliferation and survival of intestinal epithelial cells via signaling pathways such as PI3K/AKT and STAT3; they also modulate mucus secretion and immune responses to restore or maintain the physical barrier function. Farnesoid X receptor agonists reduce intestinal permeability by maintaining tight junctions in the epithelium.